DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
DEXCOM INC (DXCM) is the issuer for a notice filed on behalf of director Nicholas Augustinos to sell up to 1,550 shares of Dexcom common stock under Rule 144. The shares were acquired on May 8, 2026 through a vested RSU grant from Dexcom.
The proposed sale is listed for September 14, 2026 through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of approximately $130,231. The notice reports 377,360,765 Dexcom common shares outstanding, which is a baseline figure and not the amount being sold.
DEXCOM INC (symbol: DXCM) is the issuer of record for a Form 4 filing submitted to the SEC. Boehnlein Glenn S reported acquisition or exercise transactions in this Form 4 filing.
DEXCOM INC (DXCM) reported that director Glenn S. Boehnlein received a grant of 5,841 restricted stock units of common stock on September 10, 2026. The award is exempt from Section 16b-3 and vests in three equal annual installments from the grant date, representing a contingent right to receive one share per unit. After this grant, Boehnlein holds 5,841 shares directly and 42 shares indirectly through the Boehnlein 2017 Trust, for which he and his spouse are co-trustees. No Rule 10b5-1 trading plan is reported.
DEXCOM INC (DXCM) reports that director Glenn S. Boehnlein has filed an initial statement of beneficial ownership of securities. The filing shows 42 shares of common stock held indirectly through the Boehnlein 2017 Trust, for which he and his spouse serve as co-trustees. No purchase, sale, or derivative transactions are reported.
DexCom, Inc. (DXCM) expanded its Board of Directors to thirteen members and appointed Glenn S. Boehnlein as a director, effective September 10, 2026, with a term expiring at the 2027 annual meeting of stockholders. He will serve on the Operations & Innovation Committee and the Audit Committee as an independent director.
Under Dexcom’s non-employee director compensation program, Boehnlein received an initial equity grant of RSUs valued at $500,000, vesting annually over three years, and will be eligible for an annual RSU grant with a fair value of $347,500 starting around the 2027 annual meeting. Outstanding equity awards for non-employee directors fully accelerate upon a change in control of Dexcom.
DEXCOM, INC. (DXCM) received a notice of proposed sale of its common stock under Rule 144 by officer Jereme Sylvain. The filing covers 3,638 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $302,936.26 as of September 10, 2026.
The shares derive from restricted stock awarded on December 15, 2023 (2,920 shares) and September 8, 2024 (718 shares), and are listed for sale on NASDAQ.
DEXCOM INC (DXCM) executive Sadie Stern, EVP Chief People & Culture Officer, reported selling 2,565 shares of Common Stock on August 27, 2026 at $88.37 per share in an open-market transaction. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on May 28, 2026. After this sale, Stern holds 126,043 shares directly, including 71,903 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029.
DexCom, Inc. (DXCM) received a Rule 144 notice from officer Sadie Stern covering a potential sale of common stock. The notice lists 2,565 shares of DexCom common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate value of $226,669.05 and a proposed sale date of 08/27/2026. The shares trace to restricted stock originally acquired from the issuer, including 1,874 shares acquired on 03/08/2024 and 691 shares acquired on 12/15/2023.
DEXCOM INC (DXCM) reported that President, CEO, and Director Jacob Steven Leach had 1,451 shares of common stock withheld on 2026-08-22 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units; this is explicitly stated not to be a market sale. After this withholding, he holds 418,908 direct shares, including 142,836 unvested restricted stock units with grants from March 8, 2024, 2025, and 2026 that vest through March 8, 2029. He also has 47,296 shares held indirectly through the Gregg Family Grandchildren's Trust, with his spouse serving as trustee.
DEXCOM INC (DXCM) reported that EVP and Chief Financial Officer Jereme M. Sylvain had 1,451 shares of common stock withheld on 2026-08-22 to satisfy tax withholding and remittance obligations tied to the net settlement of restricted stock units; this was not an open-market sale. After this withholding, he holds 150,390 shares directly, including 87,094 unvested restricted stock units with grants on March 8, 2026, 2025 and 2024 that vest through dates extending to March 8, 2029.
DEXCOM INC (DXCM) reported that executive officer Michael Jon Brown had 1,451 shares of common stock withheld on August 22, 2026 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units. This was not an open-market sale. After this withholding, Brown directly holds 101,502 shares of Dexcom common stock, including 71,903 unvested restricted stock units that vest in tranches from March 8, 2024 through March 8, 2029.